Refractory Hodgkin Lymphoma
Showing 1 - 25 of 27
Metastatic Melanoma, Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Recurrent Hodgkin Lymphoma Trial in
Active, not recruiting
- Metastatic Melanoma
- +22 more
- Ipilimumab
- +3 more
-
Birmingham, Alabama
- +24 more
Jan 19, 2023
Relapsed Hodgkin Lymphoma, Refractory Hodgkin Lymphoma Trial in Worldwide (Camidanlumab Tesirine)
Active, not recruiting
- Relapsed Hodgkin Lymphoma
- Refractory Hodgkin Lymphoma
- Camidanlumab Tesirine
-
Scottsdale, Arizona
- +72 more
Dec 15, 2022
Recurrent Acute Leukemia, Recurrent B Acute Lymphoblastic Leukemia, Recurrent Blastic Plasmacytoid Dendritic Cell Tumor Trial in
Recruiting
- Recurrent Acute Leukemia
- +16 more
- Acetaminophen
- +5 more
-
Duarte, CaliforniaCity of Hope Medical Center
Nov 22, 2022
Hodgkin Lymphoma, Refractory Hodgkin Lymphoma, Relapsed Hodgkin's Disease, Adult Trial in Leon (Brentuximab Vedotin 50 MG
Recruiting
- Hodgkin Lymphoma
- +2 more
- Brentuximab Vedotin 50 MG [Adcetris]
-
Leon, Guanajuato, MexicoHospital Regional Alta Especialidad Bajio
Oct 24, 2022
Recurrent Hodgkin Lymphoma, Refractory Hodgkin Lymphoma Trial in United States (drug, other, biological)
Active, not recruiting
- Recurrent Hodgkin Lymphoma
- Refractory Hodgkin Lymphoma
- Carboplatin
- +4 more
-
Duarte, California
- +3 more
Oct 24, 2022
Recurrent Hodgkin Lymphoma, Recurrent Non-Hodgkin Lymphoma, Refractory Hodgkin Lymphoma Trial in Seattle (drug, other,
Recruiting
- Recurrent Hodgkin Lymphoma
- +3 more
- Brentuximab Vedotin
- +2 more
-
Seattle, WashingtonFred Hutch/University of Washington Cancer Consortium
Oct 4, 2022
Recurrent DLBCL, Recurrent T-Cell Non-Hodgkin Lymphoma, Refractory DLBCL Trial in Houston (drug, procedure, other, biological)
Recruiting
- Recurrent Diffuse Large B-Cell Lymphoma
- +4 more
- Busulfan
- +7 more
-
Houston, TexasM D Anderson Cancer Center
Sep 22, 2022
Hematopoietic Cell Transplantation Recipient, Refractory B-Cell Non-Hodgkin Lymphoma, Refractory Hodgkin Lymphoma Trial in
Active, not recruiting
- Hematopoietic Cell Transplantation Recipient
- +3 more
- Allogeneic Bone Marrow Transplantation
- +10 more
-
Houston, TexasM D Anderson Cancer Center
Aug 18, 2022
Relapsed Hodgkin Lymphoma, Refractory Hodgkin Lymphoma Trial in Chapel Hill (Nivolumab, Pembrolizumab)
Recruiting
- Relapsed Hodgkin Lymphoma
- Refractory Hodgkin Lymphoma
- Nivolumab
- Pembrolizumab
-
Chapel Hill, North CarolinaLineberger Comprehensive Cancer Center at University of North Ca
Jul 22, 2022
Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent DLBCL, Recurrent Hodgkin Lymphoma Trial in New York (Decitabine and
Recruiting
- Recurrent B-Cell Non-Hodgkin Lymphoma
- +5 more
- Decitabine and Cedazuridine
- Nivolumab
-
New York, New YorkNY011 Laura and Isaac Perlmutter Cancer Center at NYU Langone
Jul 8, 2022
Recurrent Hodgkin Lymphoma, Refractory Hodgkin Lymphoma Trial in Duarte (Basiliximab, Carmustine, Cytarabine)
Recruiting
- Recurrent Hodgkin Lymphoma
- Refractory Hodgkin Lymphoma
- Basiliximab
- +6 more
-
Duarte, CaliforniaCity of Hope Medical Center
Jun 16, 2022
Blastoid Variant Mantle Cell Lymphoma, Recurrent Chronic Lymphocytic Leukemia, Recurrent Follicular Lymphoma Trial in United
Active, not recruiting
- Blastoid Variant Mantle Cell Lymphoma
- +8 more
- Ibrutinib
- Laboratory Biomarker Analysis
-
Birmingham, Alabama
- +4 more
May 10, 2022
Classic Hodgkin Lymphoma, Recurrent Hodgkin Lymphoma, Refractory Hodgkin Lymphoma Trial in United States (drug, other,
Active, not recruiting
- Classic Hodgkin Lymphoma
- +2 more
- Brentuximab Vedotin
- +2 more
-
Duarte, California
- +5 more
Mar 17, 2022
Recurrent Hodgkin Lymphoma, Refractory Hodgkin Lymphoma Trial in Duarte (Brentuximab Vedotin, Cyclosporine, Pharmacokinetic
Active, not recruiting
- Recurrent Hodgkin Lymphoma
- Refractory Hodgkin Lymphoma
- Brentuximab Vedotin
- +4 more
-
Duarte, CaliforniaCity of Hope Medical Center
Feb 17, 2022
Hodgkin Lymphoma, Adult, Relapse, Refractory Hodgkin Lymphoma Trial in Tianjin (PD-1 inhibitor)
Recruiting
- Hodgkin Lymphoma, Adult
- +2 more
- PD-1 inhibitor
-
Tianjin, Tianjin, ChinaInstitute of Hematology & Blood Diseases Hospital
Dec 14, 2021
Hodgkin Lymphoma, Adult, Relapsed Hodgkin's Disease, Adult, Refractory Hodgkin Lymphoma Trial in Caba (Evaluation of
Recruiting
- Hodgkin Lymphoma, Adult
- +2 more
- Evaluation of therapeutical approach after ASCT
-
Caba, ArgentinaFUNDALEU
Oct 1, 2021
Recurrent Hodgkin Lymphoma, Refractory Hodgkin Lymphoma, Classical Hodgkin Lymphoma Trial in Atlanta (Bendamustine, Gemcitabine,
Active, not recruiting
- Recurrent Hodgkin Lymphoma
- +3 more
- Bendamustine
- +2 more
-
Atlanta, Georgia
- +1 more
Aug 25, 2021
Hodgkin Lymphoma, Refractory Hodgkin Lymphoma Trial in Lexington (Pentamidine)
Completed
- Hodgkin Lymphoma
- Refractory Hodgkin Lymphoma
-
Lexington, KentuckyUniversity of Kentucky Markey Cancer Center
Jul 6, 2021
Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Hodgkin Lymphoma, Recurrent Mantle Cell Lymphoma Trial in Seattle (procedure,
Completed
- Recurrent B-Cell Non-Hodgkin Lymphoma
- +7 more
- Autologous Hematopoietic Stem Cell Transplantation
- +7 more
-
Seattle, WashingtonFred Hutch/University of Washington Cancer Consortium
Jul 29, 2020
Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Hodgkin Lymphoma, Recurrent T-Cell Non-Hodgkin Lymphoma Trial in Seattle
Terminated
- Recurrent B-Cell Non-Hodgkin Lymphoma
- +5 more
- Autologous Hematopoietic Stem Cell Transplantation
- +2 more
-
Seattle, WashingtonFred Hutch/University of Washington Cancer Consortium
Mar 26, 2020
Prolymphocytic Leukemia, Recurrent Adult Hodgkin Lymphoma, Recurrent Childhood Hodgkin Lymphoma Trial in Salt Lake City,
Completed
- Prolymphocytic Leukemia
- +13 more
- Autologous Hematopoietic Stem Cell Transplantation
- +14 more
-
Salt Lake City, Utah
- +4 more
Jan 17, 2020
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Aggressive Non-Hodgkin Lymphoma Trial in United States (procedure, drug,
Completed
- Acute Lymphoblastic Leukemia
- +25 more
- Allogeneic Hematopoietic Stem Cell Transplantation
- +7 more
-
Aurora, Colorado
- +5 more
Dec 17, 2019
Recurrent Hodgkin Lymphoma, Refractory Hodgkin Lymphoma Trial in Rochester (Brentuximab Vedotin, Everolimus, Laboratory
Terminated
- Recurrent Hodgkin Lymphoma
- Refractory Hodgkin Lymphoma
- Brentuximab Vedotin
- +3 more
-
Rochester, MinnesotaMayo Clinic
Dec 10, 2019
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Aggressive Non-Hodgkin Lymphoma Trial in Denmark, Germany, United States
Completed
- Acute Lymphoblastic Leukemia
- +18 more
- Allogeneic Hematopoietic Stem Cell Transplantation
- +6 more
-
Denver, Colorado
- +10 more
Oct 10, 2019